CO2 Fractional Laser Therapy – MonaLisa Touch®

MonaLisa Touch® is an innovative laser procedure, designed and produced by DEKA (Italy), that delivers fractional CO2 laser energy to the vaginal wall tissue, benefiting a woman’s overall urogenital health. The procedure is performed in an office environment without the need for anesthesia and with virtually no pain or side effects. It was approved by Health Canada in 2016.

Issues of urogenital health are commonly seen in post-menopausal women, breast cancer survivors and women who have had a hysterectomy with bilateral oophorectomy. In the US, as many as 50% of 64 million post-menopausal women suffer from changes to their gynecologic health*, and over 2.8M breast cancer survivors**.
* US Census, 2010 ** National Institutes of Health 2011
The above histological images show the vaginal mucosa before and after the MonaLisa Touch® treatment. The marked change to the epithelium post-treatment is clearly illustrated.

Histological preparation of a section of the vaginal mucosa stained with haematoxylin and eosin (H&E). (A) Vaginal mucosa in the basal condition with a thinner epithelium. (B) The same patient two months after a session with the MonaLisa Touch®. The thicker epithelium and shedding of numerous big cells from the free surface, together with the larger diameter of epithelial cells rich in glycogen, demonstrate the restored metabolic trophism and dynamics of the whole epithelium. [Courtesy of Prof. A. Calligaro. University of Pavia, Italy]

Two Renewal Mechanisms in One.
  • Ablation
  • Thermal Effect
Symptoms Improvement (%) after 3 Monalisa Touch® Treatments in Menopause Patients:
  • BURNING 84%
  • ITCHING 85%
  • DRYNESS 76%
  • LAXITY 90%
*Courtesy of Prof. S.Salvatore – Hospital San Raffaele, Milan (Italy)

Bladder urgency, frequency and mild stress incontinence can also be significantly improved in menopausal patients.

Urogenital atrophy is a very common condition, especially among women in menopause (either natural or surgical) or during postpartum. The vulvovaginal region is very sensitive to estrogen decline, with a series of consequences that impact directly on the quality of a woman’s life: weakness and laxity of the vaginal mucosa, dryness, itching and burning, and pain during sexual intercourse (dyspareunia). Other related symptoms include burning with urination, the need for frequent and urgent urination, stress incontinence and recurrent urinary tract infections.

MonaLisa Touch® is the only procedure proven not only by clinical results but also by detailed ultrastructural and histological studies. Scientific publications of the results demonstrate the effective tissue regeneration achieved thanks to the unique combination of the wavelength of the CO2 laser, the structure of the D-Pulse and adequate emission power.

With MonaLisa Touch® comes a method, with a unique concept, for restoring the atrophic conditions of the urogenital region.

During menopause, the mucosa has metabolically quiescent fibrocytes as opposed to fibroblasts, unable to actively produce collagen, hyaluronic acid and other molecules needed for an adequate glycoprotein ground matrix. This can result in dry mucosa because it is dehydrated and less well-nourished, meaning it is fragile and more prone to infections. Similarly, the declining estrogen levels of menopause also creates the same picture in the tissues surrounding the bladder and urethra resulting in various forms of incontinence and recurrent bladder infections.

What clinical trials have been conducted on the MonaLisa Touch®?

A multisite study was conducted by Dr. Mickey Karram, Director of Fellowship Program on Female Pelvic Medicine & Reconstructive Surgery at The Christ Hospital, Cincinnati, OH and Dr. Eric Sokol, Associate Professor of Obstetrics and Gynecology at the Stanford University Medical Center.

The trial assessed the use of CO2 fractional laser therapy on 30 women with gynecological health issues due to natural or induced menopause. All patients in the trial were treated with the MonaLisa Touch® laser therapy. Results were:
  • Overwhelmingly positive with immediate results
  • • Highly statistically significant improvement in symptoms after first treatment
  • Escalation of progress with each subsequent treatment
*Women in the study either experienced natural menopause or induced menopause as the result of hysterectomy or drug-induced suppression of ovarian function (chemotherapy, radiations, and anticancer drugs such as Tamoxifen).

A study was done by Dr. Stefano Salvatore, Department of Obstetrics and Gynecology, Vita-Salute San Raffaele University to assess the feasibility of C02 fractional laser in the treatment of 50 women suffering changes in their gynecologic health.

42 patients (84%) showed significant improvement in their physical and mental quality of life scores over baseline and were satisfied with the treatment. Gynecologic symptoms were significantly improved.